35,327 results match your criteria Glioblastoma Multiforme


Ligand density and linker length are critical factors for multivalent nanoparticle-receptor interactions.

ACS Appl Mater Interfaces 2018 Dec 6. Epub 2018 Dec 6.

Although there is a large number of studies available evaluating the therapeutic efficacy of targeted polymeric nanoparticles, little is known about the critical attributes that can further influence their uptake into target cells. In this study, varying cRGD ligand densities (0-100% surface functionalization) were combined with different PEG spacer lengths (2/3.5/5kDa) and the specific receptor binding of targeted core-shell structured PLGA/PLA-PEG nanoparticles was evaluated using αβ integrin overexpressing U87MG glioblastoma cells. Read More

View Article
December 2018
1 Read

Antibody-assisted delivery of a peptide-drug conjugate for targeted cancer therapy.

Mol Pharm 2018 Dec 6. Epub 2018 Dec 6.

A number of cancer-targeting peptide-drug conjugates (PDCs) have been explored as alternatives to antibody-drug conjugates (ADCs) for targeted cancer therapy. However, the much shorter circulation half-life of PDCs compared with ADCs in vivo has limited their therapeutic value and thus their translation into the clinic, highlighting the need to develop new approaches for extending the half-life of PDCs. Here, we report a new strategy for targeted cancer therapy of a PDC based on a molecular hybrid between an anti-hapten antibody and a hapten-labeled PDC. Read More

View Article
December 2018
3 Reads

expression is influenced by astrocytoma grade and polymorphism.

J Cancer 2018 31;9(23):4496-4502. Epub 2018 Oct 31.

Laboratory of Molecular Neurooncology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.

Glial fibrillary acidic protein (GFAP) is an intermediate filament that provides mechanical support to astrocytes. is a single nucleotide polymorphism (SNP) located in the promoter region of the gene. The aim of this pilot study is to investigate expression at mRNA, protein levels and polymorphism in 50 different grade human astrocytoma samples. Read More

View Article
October 2018
3 Reads

NR2C2-uORF targeting UCA1-miR-627-5p-NR2C2 feedback loop to regulate the malignant behaviors of glioma cells.

Cell Death Dis 2018 Dec 5;9(12):1165. Epub 2018 Dec 5.

Department of Neurosurgery, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Accumulating evidence has highlighted the potential role of non-coding RNAs (ncRNAs) and upstream open-reading frames (uORFs) in the biological behaviors of glioblastoma. Here, we elucidated the function and possible molecular mechanisms of the effect of some ncRNAs and NR2C2-uORF on the biological behaviors of gliomas. Quantitative real-time PCR was conducted to profile the cell expression of lnc-UCA1 and microRNA-627-5p (miR-627-5p) in glioma tissues and cells. Read More

View Article
December 2018

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Acta Neuropathol Commun 2018 Dec 5;6(1):135. Epub 2018 Dec 5.

Activartis Biotech GmbH, Wilhelminenstraße 91/IIf, 1160, Vienna, Austria.

Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via "danger signals". The recent phase II "GBM-Vax" trial showed no clinical efficacy for Audencel as assessed with progression-free and overall survival in all patients. Read More

View Article
December 2018
1 Read

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas.

Cancers (Basel) 2018 Dec 4;10(12). Epub 2018 Dec 4.

Department of Neurology, Erasmus MC Cancer Institute; 3015 CD Rotterdam, The Netherlands.

The gene is one of the most frequently mutated and/or amplified gene both in lung adenocarcinomas (LUAD) and in glioblastomas (GBMs). Although both tumor types depend on the mutation for growth, clinical benefit of EGFR tyrosine kinase inhibitors (TKIs) has only been observed in LUAD patients and, thus-far, not in GBM patients. Also in LUAD patients however, responses are restricted to specific mutations only and these 'TKI-sensitive' mutations hardly occur in GBMs. Read More

View Article
December 2018
1 Read

Acid-induced Activated Cell Penetrating Peptide Modified Cholesterol-conjugated Polyoxyethylene Sorbitol Oleate Mixed Micelles for pH-triggered Drug Release and Efficient Brain Tumor Targeting Based on a Charge Reversal Mechanism.

ACS Appl Mater Interfaces 2018 Dec 3. Epub 2018 Dec 3.

Glioblastoma multiforme is the most devastating malignant brain tumor in adults. Even with standard-care of therapy, the prognosis remains dismal due to tumor heterogeneity, tumor infiltration, and more importantly, the restrictive nature of the blood-brain barrier (BBB). To overcome the challenge of effectively delivering therapeutic cargo into the brain, herein a "smart," multifunctional polymeric micelle was developed using a cholesterol-conjugated polyoxyethylene sorbitol oleate. Read More

View Article
December 2018

Evaluation of Tumor Regulatory Genes and Apoptotic Pathways in The Cytotoxic Effect of Cytochalasin H on Malignant Human Glioma Cell Line (U87MG).

Cell J 2019 Apr 18;21(1):62-69. Epub 2018 Nov 18.

Department of Aquatic Animal Health and Diseases, Iranian Fisheries Science Research Institute (IFSRI), Agricultural Research, Education and Extension Organization (AREEO), Tehran, Iran.

Objective: The aim of current study was to provide a proof-of-concept on the mechanism of PLAU and PCDH10 gene expressions and caspases-3, -8, and -9 activities in the apoptotic pathway after treatment of malignant human glioma cell line (U87MG) with cytochalasin H.

Materials And Methods: In the present experimental study, we have examined cytochalasin H cytotoxic activities as a new therapeutic agent on U87MG cells in vitro for the first time. The cells were cultured and treated with 10-10 M of cytochalasin H for 24, 48 and 72 hours. Read More

View Article
April 2019
1 Read

Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.

Glia 2018 Dec 2. Epub 2018 Dec 2.

Instituto Cajal, CSIC, Madrid, Spain.

Genetic lesions in glioblastoma (GB) include constitutive activation of PI3K and EGFR pathways to drive cellular proliferation and tumor malignancy. An RNAi genetic screen, performed in Drosophila melanogaster to discover new modulators of GB development, identified a member of the secretory pathway: kish/TMEM167A. Downregulation of kish/TMEM167A impaired fly and human glioma formation and growth, with no effect on normal glia. Read More

View Article
December 2018

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.

Brain Pathol 2018 Dec 3. Epub 2018 Dec 3.

Edinger Institute, Institute of Neurology, Goethe University, Frankfurt, Frankfurt am Main, Germany.

While the central nervous system is considered an immunoprivileged site and brain tumors display immunosuppressive features, both innate and adaptive immune responses affect glioblastoma (GBM) growth and treatment resistance. However, the impact of the major immune cell population in gliomas, represented by glioma-associated microglia/macrophages (GAMs), on patients' clinical course is still unclear. Thus, we aimed at assessing the immunohistochemical expression of selected microglia and macrophage markers in 344 gliomas (including gliomas from WHO grade I-IV). Read More

View Article
December 2018

Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.

J Neurooncol 2018 Dec 1. Epub 2018 Dec 1.

Department of Neurosurgery, University Hospital of Münster, Münster, Germany.

Background: There is an increasing interest in local tumor ablative treatment modalities that induce immunogenic cell death and the generation of antitumor immune responses.

Methods: We report six recurrent glioblastoma patients who were treated with intracavitary thermotherapy after coating the resection cavity wall with superparamagnetic iron oxide nanoparticles ("NanoPaste" technique). Patients underwent six 1-h hyperthermia sessions in an alternating magnetic field and, if possible, received concurrent fractionated radiotherapy at a dose of 39. Read More

View Article
December 2018
1 Read

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.

J Neurooncol 2018 Dec 1. Epub 2018 Dec 1.

Tel Aviv Medical Center, Tel Aviv, Israel.

Background: Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) improved progression free (PFS) and overall survival (OS) versus TMZ alone. Previous data indicate a ≥ 75% daily compliance improves outcomes. Read More

View Article
December 2018

Radiolabeled Angiogenesis-Targeting Croconaine Nanoparticles for Trimodality Imaging Guided Photothermal Therapy of Glioma.

ACS Appl Nano Mater 2018 Apr 20;1(4):1741-1749. Epub 2018 Mar 20.

Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Bethesda, Maryland 20892, United States.

To meet the criteria of effective theranostics, biocompatible nanomedicine endowing intrinsic therapeutic and imaging properties have gained extraordinary momentum. In this study, an ultra-stable near-infrared (NIR) dye croconaine (CR780) was engineered with arginine-glycine-aspartic acid (RGD) peptide and polyethylene glycol (PEG), which was then self-assembled into uniform nanoparticles (NPs). These RGD-CR780-PEG5K assemblies were radiolabeled with I through a facile standard Iodo-Gen method. Read More

View Article
April 2018
2 Reads

Dibutyltin(IV) Complexes Derived from L-DOPA: Synthesis, Molecular Docking, Cytotoxic and Antifungal Activity.

Chem Pharm Bull (Tokyo) 2018 ;66(12):1104-1113

Instituto de Química, Universidad Nacional Autónoma de México (UNAM), Circuito Exterior s/n, Ciudad Universitaria.

A series of organotin(IV) complexes was herein prepared and characterized. A one-pot synthetic strategy afforded reasonable to high yields, depending on the nature of the ligand. All new complexes were fully characterized by spectroscopic techniques, consisting of IR, MS and NMR (H, C and Sn). Read More

View Article
January 2018
1 Read

Basic principles of mathematical growth modeling applied to high-grade gliomas: A brief clinical review for clinicians.

Neurol India 2018 Nov-Dec;66(6):1575-1583

Directorate of Research, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico; I.M. Sechenov First Moscow State Medical University (Sechenov University), Department of Radiology, Moscow, Russia.

The battle against cancer has intensified in the last decade. New experimental techniques and theoretical models have been been proposed to understand the behavior, growth, and evolution of different types of brain tumors. Unfortunately, for glioblastoma multiforme (GBM), except for methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter that has some benefit in the local control of tumors using alkylating agents such as temozolomide, to date personalized treatments do not exist. Read More

View Article
December 2018

Effects of nuclear factor I phosphorylation on calpastatin (CAST) gene variant expression and subcellular distribution in malignant glioma cells.

J Biol Chem 2018 Nov 30. Epub 2018 Nov 30.

Oncology, University of Alberta, Canada.

Malignant glioma (MG) is the most lethal primary brain tumor. In addition to having inherent resistance to radiation treatment and chemotherapy, MG cells are highly infiltrative, rendering focal therapies ineffective. Genes involved in MG cell migration and glial cell differentiation are up-regulated by hypophosphorylated nuclear factor I (NFI), which is dephosphorylated by the phosphatase calcineurin in MG cells. Read More

View Article
November 2018
2 Reads

Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.

J Proteomics 2018 Nov 29. Epub 2018 Nov 29.

Clinical Neuroproteomics Group, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain; IDISNA, Navarra Institute for Health Research, Pamplona, Spain; Proteored-ISCIII, Proteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain. Electronic address:

Adenovirus Delta-24-RGD has shown a remarkable efficacy in a phase I clinical trial for glioblastoma. Delta-24-RGD induces autophagy in glioma cells, however, the molecular derangements associated with Delta-24-RGD infection remains poorly understood. Here, proteomics was applied to characterize the glioma metabolic disturbances soon after Delta-24-RGD internalization and late in infection. Read More

View Article
November 2018

Isolinderalactone regulates the BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model.

Cancer Lett 2018 Nov 29. Epub 2018 Nov 29.

Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam, 50612, Republic of Korea; Korean Medical Science Research Center for Healthy-Aging, Pusan National University, Yangsan, Gyeongnam, 50612, Republic of Korea; Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National University, Yangsan, Gyeongnam, 50612, Republic of Korea. Electronic address:

Glioblastoma multiforme (GBM) is the most common malignant brain tumor, which remains incurable. Plant extracts are a potential source of potent anticancer medicines. In this study, we investigated the effect of isolinderalactone from Lindera aggregata on tumor growth using U-87 human glioblastoma cells. Read More

View Article
November 2018
1 Read

Differentiation of primary central nervous system lymphoma from glioblastoma: Quantitative analysis using arterial-spin labeling and diffusion tensor imaging.

World Neurosurg 2018 Nov 28. Epub 2018 Nov 28.

Department of diagnostic Radiology. Kafr Elsheak faculty of medicine. Kafr Elsheak -Egypt.

Purpose: Differentiation primary central nervous system lymphoma (PCNSL) from glioblastoma through applying arterial-spin-labeling perfusion (ASL) and diffusion-tensor-imaging (DTI).

Methods: Study was done prospectively on 31 patients having a provisional diagnosis of PCNSL and glioblastoma who underwent conventional MRI, DTI, and ASL of the brain. The tumor blood flow (TBF), mean diffusivity (MD) plus fractional anisotropy (FA) of the mass were measured. Read More

View Article
November 2018

Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma.

Int J Mol Sci 2018 Nov 29;19(12). Epub 2018 Nov 29.

Department of Biology, University of Rome "Tor Vergata", 00133 Rome, Italy.

Caspase-8 was originally identified as a central player of programmed cell death triggered by death receptor stimulation. In that context, its activity is tightly regulated through several mechanisms, with the best established being the expression of FLICE-like inhibitory protein (FLIP) family proteins and the Src-dependent phosphorylation of Caspase-8 on Tyr380. Loss of apoptotic signaling is a hallmark of cancer and indeed Caspase-8 expression is often lost in tumors. Read More

View Article
November 2018
1 Read

Near-infrared Fluorescent Peptides with High Tumor Selectivity: Novel Probes for Image-Guided Surgical Resection of Orthotopic Glioma.

Mol Pharm 2018 Dec 5. Epub 2018 Dec 5.

The complete excision of glioblastomas with maximal retention of surrounding normal tissues can significantly improve patient prognosis. Near-infrared fluorescence (NIRF) optical imaging of the tumor vasculature offers a non-invasive method for detection of early-stage glioblastoma and efficient monitoring of therapeutic responses. The aim of this study was to develop a novel NIRF imaging probe as a visualization tool for image-guided surgical resection of orthotopic glioblastoma. Read More

View Article
December 2018

Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.

Clin Nucl Med 2018 Dec 3. Epub 2018 Dec 3.

Department of Nuclear Medicine, Radiology, NeuroRadiology, Clinical Pathology, S. Maria della Misericordia Hospital, Rovigo, Italy.

Purpose: With the advent of the revised WHO classification from 2016, molecular features, including isocitrate dehydrogenase (IDH) mutation have become important in glioma subtyping. This pilot trial analyzed the potential for C-methionine (MET) PET/MRI in classifying glioma according to the revised WHO classification using a machine learning model.

Methods: Patients with newly diagnosed WHO grade II-IV glioma underwent preoperative MET-PET/MRI imaging. Read More

View Article
December 2018
1 Read

A triple drug combination as a novel anti-glioma therapy?

Oncotarget 2018 Nov 6;9(87):35719-35720. Epub 2018 Nov 6.

Markus D. Siegelin: Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, U.S.A.

View Article
November 2018

Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma.

Clin Cancer Res 2018 Dec 4. Epub 2018 Dec 4.

U.O.C. Oncologia Medica 1, Istituto Oncologico Veneto, IRCCS.

Purpose: In-depth characterization of recurrent glioblastoma (rGBM) might contribute to a better understanding of the mechanisms behind tumor progression and enable rGBM treatment with targeted drugs.

Experimental Design: In this study, GBM samples were collected at diagnosis and recurrence from adult patients treated with Stupp protocol. Expression of mismatch repair (MMR) proteins was evaluated by IHC, followed by whole exome sequencing (WES) of tumor samples showing loss of MSH6 reactivity. Read More

View Article
December 2018

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials.

Clin Cancer Res 2018 Dec 4. Epub 2018 Dec 4.

Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and University of Zurich.

Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically optimized cutoff was sought allowing patient selection for therapy without temozolomide, while avoiding to withhold it from patients who may potentially benefit.

Experimental Design: Quantitative MGMT methylation-specific PCR data were obtained for newly diagnosed glioblastoma patients screened or treated with standard radiotherapy and temozolomide in four randomized trials. Read More

View Article
December 2018

The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line.

BMC Cancer 2018 Dec 4;18(1):1213. Epub 2018 Dec 4.

Univ Rennes, CNRS, IGDR [(Institut de génétique et développement de Rennes)]-UMR 6290, F-35000, Rennes, France.

Background: Glioblastoma (GB) is a highly invasive primary brain tumor that nearly always systematically recurs at the site of resection despite aggressive radio-chemotherapy. Previously, we reported a gene expression signature related to tumor infiltration. Within this signature, the EMX2 gene encodes a homeodomain transcription factor that we found was down regulated in glioblastoma. Read More

View Article
December 2018
1 Read

EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.

BMC Cancer 2018 Dec 4;18(1):1215. Epub 2018 Dec 4.

Department of pharmacy, the Second Clinical College, Harbin Medical University, Harbin, People's Republic of China.

Background: Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of GBM cells to TMZ is affected by many factors. Read More

View Article
December 2018
3.362 Impact Factor

Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.

Radiol Oncol 2018 Nov 26;52(4):422-432. Epub 2018 Nov 26.

Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Background Glioblastoma (GBM) is the most common and the most malignant glioma subtype. Among numerous genetic alterations, miRNAs contribute to pathogenesis of GBM and it is suggested that also to GBM recurrence and resistance to therapy. Based on publications, we have selected 11 miRNAs and analyzed their expression in GBM. Read More

View Article
November 2018

High level EGFR amplification in a newly established glioblastoma cell line 170-MG-BA.

Neoplasma 2018 Aug 9. Epub 2018 Aug 9.

Department of Anatomy, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Glioblastoma multiforme is a highly invasive and incurable primary brain tumor. The most frequent genetic alteration therein is amplification of the epidermal growth factor receptor (EGFR) gene, the target of current clinical trials. However, EGFR amplification is poorly adapted to glioblastoma cell lines. Read More

View Article

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Neuro Oncol 2018 Nov 30. Epub 2018 Nov 30.

Kurume University School of Medicine, Fukuoka, Japan.

Background: We conducted a phase III trial of personalized peptide vaccination (PPV) for human leucocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality.

Methods: We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n=58) or the placebo (n=30) at a 2-to-1 ratio. Four of 12 warehouse peptides selected based on preexisting peptide-specific IgG levels or the corresponding placebos were injected 1/week for 12 weeks. Read More

View Article
November 2018
2 Reads

Use of DNA-generated gold nanoparticles to radiosensitize and eradicate radioresistant glioma stem cells.

Nanotechnology 2019 Feb 30;30(5):055101. Epub 2018 Nov 30.

Core Research for Evolutionary Science and Technology (CREST), Japan Science and Technology Agency (JST), 3-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan. Graduate School of Natural Science and Technology, Okayama University, 3-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.

The surface reactivity of gold nanoparticles (AuNPs) is receiving attention as a radiosensitizer of cancer cells for radiation therapy and/or as a drug carrier to target cells. This study demonstrates the potential of DNA-AuNPs (prepared by mixing calf thymus DNA with HAuCl solution) as a radiosensitizer of human glioma cells that have cancer stem cell (CSC)-like properties, to reduce their survival. CSC-like U251MG-P1 cells and their parental glioblastoma U251MG cells are treated with a prepared DNA-AuNP colloid. Read More

View Article
February 2019

Therapeutic nanoplatforms and delivery strategies for neurological disorders.

Nano Converg 2018 Nov 30;5(1):35. Epub 2018 Nov 30.

Department of Mechanical Engineering and Engineering Science, Center for Biomedical Engineering and Science, Department of Biological Sciences, The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA.

The major neurological disorders found in a central nervous system (CNS), such as brain tumors, Alzheimer's diseases, Parkinson's diseases, and Huntington's disease, have led to devastating outcomes on the human public health. Of these disorders, early diagnostics remains poor, and no treatment has been successfully discovered; therefore, they become the most life-threatening medical burdens worldwide compared to other major diseases. The major obstacles for the drug discovery are the presence of a restrictive blood-brain barrier (BBB), limiting drug entry into brains and undesired neuroimmune activities caused by untargeted drugs, leading to irreversible neuronal damages. Read More

View Article
November 2018
3 Reads

Safety and efficacy of targeted alpha therapy with Bi-DOTA-substance P in recurrent glioblastoma.

Eur J Nucl Med Mol Imaging 2018 Nov 29. Epub 2018 Nov 29.

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for the tumor cell targeting. Targeted alpha therapy with DOTA-Substance P labeled with the short range alpha emitter Bi allows for selective irradiation and killing of tumor cells. Read More

View Article
November 2018
3 Reads

The STAT3 and hypoxia pathways converge on Vasorin to promote stemness and glioblastoma tumorigenesis through Notch1 stabilization.

Stem Cell Investig 2018 22;5:35. Epub 2018 Oct 22.

Department of Pathology and Laboratory Medicine, and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.

View Article
October 2018

Cross-talk between tumor stem cells and tumor cells: a glioblastoma strategy to promote malignancy.

Authors:
Laura Riboni

Stem Cell Investig 2018 10;5:32. Epub 2018 Oct 10.

Department of Medical Biotechnology and Translational Medicine, LITA-Segrate, University of Milan, Italy.

View Article
October 2018

Molecular Ultrasound Assessment of Glioblastoma Neovasculature with Endoglin-Targeted Microbubbles.

Contrast Media Mol Imaging 2018 18;2018:8425495. Epub 2018 Oct 18.

Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong SAR, China.

Objectives: Glioblastoma, as one of the most malignant cancer in the world, usually shows substantially increased angiogenesis. Endoglin (CD105), which is an alternative proangiogenic growth factor, has been remarkably upregulated on the proliferating glioblastoma neovasculature. However, little is known on the noninvasive assessment of the expression levels of CD105 during glioblastoma progression. Read More

View Article
October 2018

Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation.

Clin Cancer Res 2018 Nov 29. Epub 2018 Nov 29.

Neurosurgery, David Geffen School of Medicine at UCLA

Purpose: Glioblastoma (GBM) is the most common primary malignant tumor in the central nervous system. Our recent pre-clinical work has suggested that PD-1/PD-L1 plays an important immunoregulatory role to limit effective anti-tumor T cell responses induced by active immunotherapy. However, little is known about the functional role that PD-1 plays on human T lymphocytes in malignant glioma patients. Read More

View Article
November 2018
3 Reads

Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.

Cancer Res 2018 Nov 29. Epub 2018 Nov 29.

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan.

Glioblastoma (GBM) is a highly aggressive form of cancer that is resistant to standard therapy with concurrent radiation and temozolomide, two agents that work by inducing DNA damage. An underlying cause of this resistance may be a subpopulation of cancer stem-like cells that display a heightened DNA damage response (DDR). Although this DDR represents an attractive therapeutic target for overcoming the resistance of GBMs to radiotherapy, until now, the cause of this DDR upregulation has not been understood. Read More

View Article
November 2018
3 Reads

SWIM tool application to expression data of glioblastoma stem-like cell lines, corresponding primary tumors and conventional glioma cell lines.

BMC Bioinformatics 2018 Nov 30;19(Suppl 15):436. Epub 2018 Nov 30.

Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Via dei Taurini 19, Rome, 00185, Italy.

Background: It is well-known that glioblastoma contains self-renewing, stem-like subpopulation with the ability to sustain tumor growth. These cells - called cancer stem-like cells - share certain phenotypic characteristics with untransformed stem cells and are resistant to many conventional cancer therapies, which might explain the limitations in curing human malignancies. Thus, the identification of genes controlling the differentiation of these stem-like cells is becoming a successful therapeutic strategy, owing to the promise of novel targets for treating malignancies. Read More

View Article
November 2018
1 Read

Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review.

J Immunoassay Immunochem 2018 Nov 30:1-11. Epub 2018 Nov 30.

a Department of Biochemistry , University of Medicine and Pharmacy of Craiova , Craiova , Romania.

In recent years, immunotherapy has raised the interest of many studies and provided different perspectives for the therapeutic management of high grade glioma. Our meta-analysis focused on the effectiveness of dendritic cell (DC) therapy and viral therapy (VT) in clinical trials. Fourteen eligible studies have been evaluated and the results suggest the improvement of both OS (HR = 0. Read More

View Article
November 2018

A familial syndrome of hypothalamic hamartomas, polydactyly, and SMO mutations: a clinical report of 2 cases.

Authors:

J Neurosurg Pediatr 2018 Oct 1:1-6. Epub 2018 Oct 1.

Hypothalamic hamartomas are benign tumors known to cause gelastic or dacrystic seizures, precocious puberty, developmental delay, and medically refractory epilepsy. These tumors are most often sporadic but rarely can be associated with Pallister-Hall syndrome, an autosomal dominant familial syndrome caused by truncation of glioblastoma transcription factor 3, a downstream effector in the sonic hedgehog pathway. In this clinical report, the authors describe two brothers with a different familial syndrome. Read More

View Article
October 2018

Peiminine Inhibits Glioblastoma in Vitro and in Vivo Through Cell Cycle Arrest and Autophagic Flux Blocking.

Cell Physiol Biochem 2018 Nov 29;51(4):1566-1583. Epub 2018 Nov 29.

Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin,

Background/aims: Glioblastoma multiforme (GBM) is the most devastating and widespread primary central nervous system tumour in adults, with poor survival rate and high mortality rates. Existing treatments do not provide substantial benefits to patients; therefore, novel treatment strategies are required. Peiminine, a natural bioactive compound extracted from the traditional Chinese medicine Fritillaria thunbergii, has many pharmacological effects, especially anticancer activities. Read More

View Article
November 2018

miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker.

Mol Ther Nucleic Acids 2018 Sep 13;13:642-650. Epub 2018 Sep 13.

Equipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO)Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire)Université de Nantes, Nantes, France; LabEX IGO, Université de Nantes, Nantes, France. Electronic address:

In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the "Prognostic miRNA Database" indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. Read More

View Article
September 2018
1 Read

Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

Int J Radiat Oncol Biol Phys 2018 Nov 26. Epub 2018 Nov 26.

University of Maryland Medical Systems, Baltimore, MD (during trial) - Miami Cancer Institute, Coral Gables, FL (current).

Purpose: Evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months following concurrent chemo-radiation in newly diagnosed glioblastoma (GBM).

Methods: Trial XXXX, a single arm, multi-institutional phase 2 trial was designed to determine the efficacy and toxicity of concomitant TMZ and radiation (RT) followed by adjuvant TMZ combined with CPT-11 given for 12 cycles compared to historical controls of adjuvant TMZ alone given for 6 cycles.

Results: A total of 170 patients were enrolled, of which 152 were eligible. Read More

View Article
November 2018

Molecular features of pleomorphic xanthoastrocytoma.

Hum Pathol 2018 Nov 26. Epub 2018 Nov 26.

Department of Pathology, Xiangya Hospital, Central South University, Changsha, China; Department of Pathology, Xiangya Medical School, Central South University, Changsha; Department of Pathology, Institute of Basic Medicine, Xinjiang Medical University, Urumqi, China. Electronic address:

Pleomorphic xanthoastrocytoma (PXA) is a rare central nervous system tumor occurring mostly in children and young adults. Next-generation sequencing of 295 cancer-related genes was used to investigate the molecular profiles of 13 cases of PXA. We found that BRAF V600E (5/13; 38%), FANCA/D2/I/M (5/13; 38%), PRKDC (4/13; 31%), NF1 (3/13; 23%), and NOTCH2/3/4 (3/13; 23%) alterations were the most frequent somatic gene mutations. Read More

View Article
November 2018
2 Reads

EMT-like process in glioblastomas and reactive astrocytes.

Neurochem Int 2018 Nov 26;122:139-143. Epub 2018 Nov 26.

Departamento de Ciências Básicas da Saúde e Laboratório de Biologia Celular, Universidade Federal de Ciências da Saúde de Porto Alegre- UFCSPA, Porto Alegre, RS, Brazil. Electronic address:

The concept of the epithelial-to-mesenchymal transition (EMT) in epithelial cells has accelerated our understanding about cancer spreading. Fortunately, much of this information has been able to be extrapolated to non-epithelial cancers, such as glioblastoma (GBM). Interestingly, reactive astrocytes, which are present in the tumor edge in association with glioma cells, might also undergo EMT-like under stimuli of GBM cells. Read More

View Article
November 2018

Financially Effective Test-Algorithm to Identify an Aggressive, EGFR-amplified Variant of IDH-Wildtype, Lower-Grade Diffuse Glioma.

Neuro Oncol 2018 Nov 28. Epub 2018 Nov 28.

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Background: cIMPACT-NOW update 3 recognizes amplification of EGFR as one important aberration in diffuse gliomas (WHO grade II/III). While these recommendations endorse testing, a cost-effective, clinically relevant testing paradigm is currently lacking. Here, we use real-world clinical data to propose a financially effective diagnostic test-algorithm in the context of new guidelines. Read More

View Article
November 2018

Parallel comparison of pre-conditioning and post-conditioning effects in human cancers and keratinocytes upon acute gamma irradiation.

Int J Radiat Biol 2018 Nov 29:1-31. Epub 2018 Nov 29.

b Department of Biology , McMaster University , Hamilton , ON , Canada.

Purpose: To determine and compare the effects of pre-conditioning and post-conditioning towards gamma radiation responses in human cancer cells and keratinocytes MATERIALS AND METHODS: The clonogenic survival of glioblastoma cells (T98G), keratinocytes (HaCaT), and colorectal carcinoma cells (HCT116 p53 and p53) was assessed following gamma ray exposure from a Cs-137 source. The priming dose preceded the challenge dose in pre-conditioning whereas the priming dose followed the challenge dose in post-conditioning. The priming dose was either 5 mGy or 0. Read More

View Article
November 2018

Cytogenetic damage from hyperthermia,6 MV X-rays, and topotecan in glioblastoma spheroids, simultaneously, and separately.

J Cancer Res Ther 2018 Oct-Dec;14(6):1273-1278

Department of Radiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Purpose: Glioblastoma multiform (GBM) is one of the most common brain tumors. Surgery, radiation therapy, hyperthermia, and chemotherapy are the most common treatments for brain tumors such as GBM. This study investigated the cytogenetic damage caused by hyperthermia, radiation (6 MV-X-rays), and topotecan in glioma spheroids, simultaneously and separately. Read More

View Article
November 2018

Impact of subventricular zone irradiation on outcome of patients with glioblastoma.

J Cancer Res Ther 2018 Oct-Dec;14(6):1202-1206

Department of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.

Purpose: Glioblastoma (GBM) is characterized by early relapse and mortality. Treatment resistance could be a characteristic exhibited by pro-genitor neoplastic cells that reside in the subventricular zone (SVZ). This retrospective study was conducted to assess the correlation of SVZ doses and survival in patients with GBM. Read More

View Article
November 2018
2 Reads